Literature DB >> 9450621

The effects of levosimendan on [Ca2+]i in guinea-pig isolated ventricular myocytes.

M K Lancaster1, S J Cook.   

Abstract

Ca2+-sensitising agents offer a new approach to the treatment of congestive heart failure. This study examined the effects of the Ca2+-sensitising agent, levosimendan, on contraction and [Ca2+]i in guinea-pig ventricular myocytes. Levosimendan 100 nM produced an increase in cell shortening without affecting the [Ca2+]i transient or the Ca2+ content of the sarcoplasmic reticulum. 1 microM levosimendan increased the rate of decay of the [Ca2+]i transient and increased the Ca2+ content of the sarcoplasmic reticulum. These results suggest that at therapeutically relevant concentrations levosimendan can produce a significant inotropic effect without affecting [Ca2+]i but at higher concentrations may also inhibit phosphodiesterase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9450621     DOI: 10.1016/s0014-2999(97)01362-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Levosimendan.

Authors:  D P Figgitt; P S Gillies; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c.

Authors:  Tia Sorsa; Piero Pollesello; R John Solaro
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

Review 3.  Levosimendan: a review of its use in the management of acute decompensated heart failure.

Authors:  Carmen A Innes; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.

Authors:  László Nagy; Piero Pollesello; Zoltán Papp
Journal:  J Cardiovasc Pharmacol       Date:  2014-09       Impact factor: 3.105

5.  Levosimendan in pulmonary hypertension and right heart failure.

Authors:  Mona Sahlholdt Hansen; Asger Andersen; Jens Erik Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2018-07-06       Impact factor: 3.017

6.  Simultaneous LC-ESI-MS/MS Quantification of Levosimendan and Its Metabolites for Therapeutic Drug Monitoring of Cardiac Surgery Patients.

Authors:  Hannah Kipka; Roland Tomasi; Max Hübner; Uwe Liebchen; Christian Hagl; Klaus T Wanner; Hanna Mannell; Georg Höfner
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

Review 7.  Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.

Authors:  Bernard Cholley; Bruno Levy; Jean-Luc Fellahi; Dan Longrois; Julien Amour; Alexandre Ouattara; Alexandre Mebazaa
Journal:  Crit Care       Date:  2019-11-29       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.